Sandbox/01

Jump to navigation Jump to search

WikiDoc Resources for Sandbox/01

Articles

Most recent articles on Sandbox/01

Most cited articles on Sandbox/01

Review articles on Sandbox/01

Articles on Sandbox/01 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sandbox/01

Images of Sandbox/01

Photos of Sandbox/01

Podcasts & MP3s on Sandbox/01

Videos on Sandbox/01

Evidence Based Medicine

Cochrane Collaboration on Sandbox/01

Bandolier on Sandbox/01

TRIP on Sandbox/01

Clinical Trials

Ongoing Trials on Sandbox/01 at Clinical Trials.gov

Trial results on Sandbox/01

Clinical Trials on Sandbox/01 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sandbox/01

NICE Guidance on Sandbox/01

NHS PRODIGY Guidance

FDA on Sandbox/01

CDC on Sandbox/01

Books

Books on Sandbox/01

News

Sandbox/01 in the news

Be alerted to news on Sandbox/01

News trends on Sandbox/01

Commentary

Blogs on Sandbox/01

Definitions

Definitions of Sandbox/01

Patient Resources / Community

Patient resources on Sandbox/01

Discussion groups on Sandbox/01

Patient Handouts on Sandbox/01

Directions to Hospitals Treating Sandbox/01

Risk calculators and risk factors for Sandbox/01

Healthcare Provider Resources

Symptoms of Sandbox/01

Causes & Risk Factors for Sandbox/01

Diagnostic studies for Sandbox/01

Treatment of Sandbox/01

Continuing Medical Education (CME)

CME Programs on Sandbox/01

International

Sandbox/01 en Espanol

Sandbox/01 en Francais

Business

Sandbox/01 in the Marketplace

Patents on Sandbox/01

Experimental / Informatics

List of terms related to Sandbox/01

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2].

Overview

Glanzmann's thrombasthenia is an extremely rare disorder of the blood, in which the platelets lack glycoprotein IIb/IIIa. Hence, no fibrinogen bridging can occur, and bleeding time is significantly prolonged.

Pathophysiology

The GpIIb/IIIa is an adhesion receptor and is expressed in thrombocytes. This receptor is activated when the thrombocyte is stimulated by ADP, epinephrine, collagen and thrombin. The GpIIb/IIIa integrin is essential to the blood coagulation since it has the ability to bind fibrinogen, the von Willebrand factor, fibronectin and vitronectin. This enables the platelet to be activated by contact with the collagen-von Willebrand-complex that is exposed when the endothelial blood vessel lining is damaged and then aggregate with other thrombocytes via fibrinogen.

Patients suffering from Glanzmann's thrombasthenia thus have platelets less able to adhere to each other and to the underlying tissue of damaged blood vessels.

The understanding of its pathophysiology led to the development of GpIIb/IIIa inhibitors, a class of powerful antiplatelet agents.[1]

Etiology

Glanzmann's thrombasthenia can be inherited in an autosomal recessive manner[1] or acquired as an autoimmune disorder.[2]

Clinical Features

Characteristically, there is increased mucosal bleeding:

The bleeding tendency is variable but may be severe.

Patients present with moderate bleeding and normal platelet morphology. Aggregation of platelets occurs in response to ristocetin, but not to other agonists such as ADP, thrombin, collagen or adrenalin.

Eponym

It is named for Eduard Glanzmann.[3][4]

Physical examination

Gallery

Extremities

References

  1. 1.0 1.1 Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.
  2. Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol. 2004 Oct;127(2):209-13. PMID 15461628.
  3. Template:WhoNamedIt
  4. W. E. Glanzmann. Hereditäre hämorrhägische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen. Jahrbuch für Kinderheilkunde, 1918; 88: 1-42, 113-141.